Share information
261.00 €
+0.15 %
03/02/2026 17:35
+0.15 %
Open
High
Low
Volume
262.00 €
264.50 €
257.60 €
177,171
Latest News
30-Jan-2026
KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)
13-Jan-2026
Innovation and Execution Power UCB’s Success
08-Dec-2025
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
05-Dec-2025
UCB Upgrades 2025 Financial Guidance Based on Strong Performance